Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study - Archive ouverte HAL
Article Dans Une Revue Digestive and Liver Disease Année : 2024

Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study

Domaines

Cancer

Dates et versions

hal-04547885 , version 1 (16-04-2024)

Identifiants

Citer

Anne-Esther Frydman, Antoine Drouillard, Emilie Soularue, Olivier Dubreuil, Aziz Zaanan, et al.. Addition of trastuzumab to perioperative chemotherapy in HER2-positive gastroesophageal adenocarcinoma patients: A multicenter retrospective observational AGEO study. Digestive and Liver Disease, 2024, 56 (1), pp.198-205. ⟨10.1016/j.dld.2023.06.007⟩. ⟨hal-04547885⟩
10 Consultations
0 Téléchargements

Altmetric

Partager

More